slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 224,131-224,160
Pages 10,126
Rows per page 30
Component
224,131-224,160 of 303,780
02
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
03
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
The slide presents clinical validation data for the ColoAlert diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
10
The slide uses a minimalist design with a halftone dot pattern and the company logo.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the biological progression of CRC.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
AA = Advanced Adenoma; CRC = Colorectal Cancer. Data source cited at bottom.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
13
The slide uses a horizontal timeline to contrast current (2023-2024) and future (2024-2025) clinical trial phases.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
16
Data presented in a summary table and two pie charts showing disease staging distribution.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
17
Includes a highlighted box emphasizing the performance of the DNA+mRNA+FIT test for CRC and AA.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
The slide uses two scatter plots to compare sensitivity vs specificity for CRC and AA, with Mainz Biomed highlighted as a top performer.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
20
Includes a legend for commercial launch stars and mentions future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
21
Slide 21 of a pitch deck.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
23
The slide uses a grid layout to present 10 advisors with headshots, titles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
24
The timeline uses a DNA double-helix motif to represent the company's focus on molecular diagnostics.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
25
Includes income statement highlights and balance sheet data.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
Includes a highlighted box emphasizing the primary performance metrics for CRC and AA detection.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
The slide uses two scatter plots to compare diagnostic performance metrics against competitors like Guardant Health, Cologuard, and CellMax Life.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market SizeLoop · Mece Breakdown1 hit
20
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Mece Breakdown1 hit
21
Includes a footer note about future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
22
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
24
The slide uses a grid layout to present 10 key advisors with headshots, titles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
25
The slide uses a DNA double-helix motif to represent the company's focus on molecular diagnostics.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
26
Includes unaudited financial results and balance sheet data.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
27
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
28
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit